Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial

Authors: Morley, Kirsten C.1; Teesson, Maree2; Reid, Sophie C.3; Sannibale, Claudia; Thomson, Clare3; Phung, Nghi4; Weltman, Martin; Bell, James R.; Richardson, Kylie1; Haber, Paul S.

Source: Addiction, Volume 101, Number 10, October 2006 , pp. 1451-1462(12)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Aim 

To compare the efficacy of acamprosate and naltrexone in the treatment of alcohol dependence. Design 

A double-blind, placebo-controlled trial. Setting 

Three treatment centres in Australia. Participants 

A total of 169 alcohol dependent subjects were given naltrexone (50 mg/day), acamprosate (1998 mg/day) or placebo for 12 weeks. Intervention 

All subjects were offered manualized compliance therapy, a brief intervention that targets problems that may affect treatment compliance such as ambivalence and misperceptions about medication. Measurements 

Time to the first drink, time to first relapse, drinks per drinking day and cumulative abstinence. Findings 

In intention-to-treat analyses, there were no differences between groups on outcome measures of drinking, craving or biochemical markers. Similarly, analyses of the 94 subjects that completed the study in full and demonstrated 80% compliance, revealed no significant treatment effects. Differential treatment effects were identified after stratification according to scores on the Alcohol Dependence Scale (ADS) and Depression Anxiety and Stress Scale (DASS). A significant beneficial treatment effect on time to first relapse was revealed for subjects with `no depression' allocated to naltrexone (n = 56; P < 0.01). In addition, a significant beneficial treatment effect was revealed in subjects with `low dependence' allocated to naltrexone (n = 34; P < 0.05). Conclusions 

The results of this study support the efficacy of naltrexone in the relapse prevention of alcoholism amongst those with low levels of clinical depression and alcohol dependence severity. No effect of acamprosate was found in our sample.

Keywords: Acamprosate; alcohol dependence; compliance therapy; naltrexone; pharmacotherapy

Document Type: Research article

DOI: 10.1111/j.1360-0443.2006.01555.x

Affiliations: 1: Central and 2: Clinical School of Medicine, University of Sydney, NSW, Australia, National Drug and Alcohol Research Centre, University of New South Wales, NSW, Australia, 3: Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 4: Department of Drug and Alcohol Medicine, Nepean Hospital, NSW, Australia,

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$49.48 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A